Therefore, these data point out the clinical benefit of CDK4/6 inhibitors plus anti-HER2 therapies to overcome resistance in some cohorts, suggesting the need for further clinical trials to introduce CDK4/6 inhibitors in the therapeutic strategy of advanced HER2/HR BC. The gene discussed is ERBB2; the disease is breast cancer.